NVCN - Neovasc Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.4982
+0.0272 (+5.77%)
As of 1:09PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close0.4710
Open0.4800
Bid0.4940 x 1400
Ask0.4985 x 800
Day's Range0.4699 - 0.5200
52 Week Range0.3700 - 5.0000
Volume1,568,585
Avg. Volume2,036,120
Market Cap35.08M
Beta (3Y Monthly)2.63
PE Ratio (TTM)N/A
EPS (TTM)-1.4810
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.88
Trade prices are not sourced from all markets
  • PR Newswire5 days ago

    Neovasc Announces Closing of Private Placement of Convertible Debt and Common Shares for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 16, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN) announced today that it has closed its previously announced private placement (the "Private Placement") of (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company (the "Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering"). The Company relied upon the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the Toronto Stock Exchange will not apply its standards to certain transactions involving eligible interlisted issuers on a recognized exchange, such as the Nasdaq Capital Market.

  • PR Newswire7 days ago

    Neovasc Announces Private Placement of Convertible Debt and Equity for Gross Proceeds of US$11.5 Million

    VANCOUVER, May 14, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that it has entered into an agreement to sell to Strul Medical Group LLC ("SMG") (i) a 15% original issue discount convertible debenture (the "Debenture") with a face value of US$11.5 million, for gross proceeds to the Company of US$9,775,000, and (ii) 3,349,514 common shares of the Company ("Common Shares") at a price of US$0.515 per Common Share, for gross proceeds to the Company of US$1,725,000 (collectively, the "Offering").

  • Associated Press12 days ago

    Neovasc: 1Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had a loss of 21 cents per share. Losses, adjusted for asset impairment costs, came to 20 cents per share. The medical device company posted revenue ...

  • CNW Group12 days ago

    /C O R R E C T I O N from Source -- Neovasc Inc./

    The news release, Neovasc Announces First Quarter 2019 Financial Results, published at 4:00 p.m. ET on May 9, 2019 inadvertently included a statement that the Company had announced a financing. While the Company is always considering ways to improve its capital position on terms that the Company believes are favorable, there can be no assurance that any financing will be completed.

  • PR Newswire15 days ago

    Neovasc Announces Treatment of 1,000th Refractory Angina Patient with Neovasc Reducer™

    This is especially true when these people suffer from refractory angina, which is angina that persists despite optimal drug therapy and revascularization. "We are pleased to have treated the 1,000th patient to receive the Reducer therapy at the Inselspital Universitätsspital Bern". The Reducer therapy now totals medical evidence spanning 1,000 patients and 14 years of follow up.

  • PR Newswire18 days ago

    Neovasc to Announce First Quarter 2019 Financial Results on Thursday, May 9th

    Conference Call Scheduled for 4:30 pm Eastern Time on May 9 th   NASDAQ, TSX: NVCN VANCOUVER , May 3, 2019 /PRNewswire/ - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN) (TSX: ...

  • PR Newswire25 days ago

    Neovasc Provides Highlights from Annual Conference of the DGK, the German Society of Cardiology; Symposium Generates Growing Support for Reducer

    VANCOUVER, April 26, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today provided highlights from the  85th Annual Conference of the German Society of Cardiology ("DGK"), which is taking place in Mannheim, Germany, April 24 – 27, 2019. Prof. Gori (Mainz) and Prof. Reinecke (Münster) chaired a symposium on the Reducer, which included presentations from several physicians, incl.

  • CNW Grouplast month

    Neovasc Announces Resolution of Last Remaining Active Litigation

    VANCOUVER , April 17, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Company has resolved the three claims for correction of patent inventorship made by Edwards Lifesciences CardiAQ LLC ("CardiAQ") in the United States District Court for the District of Massachusetts ("the Court"). Its products include the Neovasc Reducer™ (the "Reducer"), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States , Canada and Europe .

  • PR Newswirelast month

    Neovasc Announces Peer Reviewed Publication in the International Journal of Cardiology Demonstrating that the Neovasc Reducer™ Improves Diastolic Function in patients suffering from severe angina

    VANCOUVER, April 17, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the International Journal of Cardiology (the "IJC") has published a peer reviewed article demonstrating that coronary sinus ("CS") narrowing through the use of the Neovasc Reducer™ (the "Reducer") improves diastolic function and relaxation of the heart. "We are pleased to report evidence that CS narrowing may also improve diastolic function in patients with chronic refractory angina and proven myocardial ischemia.

  • Associated Press2 months ago

    Neovasc: 4Q Earnings Snapshot

    The Richmond, British Columbia-based company said it had profit of 51 cents per share. Losses, adjusted for non-recurring gains, were 15 cents per share. The medical device company posted revenue of $523,400 ...

  • PR Newswire2 months ago

    Neovasc Announces Fourth Quarter and Fiscal Year 2018 Financial Results

    NASDAQ, TSX: NVCN Recent Highlights The U.S. Food and Drug Administration (the "FDA") granted Breakthrough Device designation to the Neovasc Reducer™ (the "Reducer") for the treatment ...

  • PR Newswire2 months ago

    Neovasc Wins German Court Appeal; Announces German Court's Decision to Dismiss CardiAQ's Claim to Co-inventorship of a European Patent for Tiara™

    VANCOUVER, March 21, 2019 /PRNewswire/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that the Higher Regional Court in Munich, Germany, on appeal by Neovasc, has dismissed the case in full, brought by Edwards Lifesciences CardiAQ LLC ("CardiAQ") against Neovasc in Germany. In this case, CardiAQ had originally claimed full ownership rights to one of Neovasc's European patent applications for its Tiara™ ("Tiara").

  • CNW Group2 months ago

    Reducer Featured in Presentation at American College of Cardiology's Annual Meeting

    VANCOUVER , March 19, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NVCN)(NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today announced that data on the Neovasc Reducer™ ("Reducer") was featured in session 725, titled, "Refractory Angina: Options for Patients With "No Options"" at the American College of Cardiology's ("ACC") 68th Annual Scientific Session and Expo ("ACC.19"). "We are pleased that today's ACC.19 session included an overview of our Reducer and its efficiency in narrowing the coronary sinus in refractory angina patients, which has resulted in an improvement in symptoms and quality of life for patients with refractory angina who were not candidates for revascularization.  A portion of the data discussed during the session was originally published in the New England Journal of Medicine in February 2015 1," stated Fred Colen , CEO of Neovasc.

  • CNW Group2 months ago

    Neovasc Announces Closing of $5 Million Public Offering of Common Shares

    VANCOUVER , March 15, 2019 /CNW/ - Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN / TSX: NVCN) announced today that it has closed its previously announced underwritten public offering (the "Offering") of 11,111,111 common shares of the Company (the "Common Shares") at a price to the public of US$0 .45 per Common Share, for aggregate gross proceeds to the Company of approximately US$5 million , before deducting the underwriting commission and Offering expenses payable by the Company.